Symbols

RLMD

Relmada Therapeutics·NASDAQ

--(--)

RLMD fundamentals

RLMD Q4 2025 Earnings

Relmada Therapeutics (RLMD) released its earnings on Mar 19, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.27 (YoY +56.45%), missed estimates.

Revenue / YoY

EPS / YoY

-0.27

+56.45%

Report date

Mar 19, 2026

RLMD Earnings Call Summary for Q4,2025

NDB01 Phase II Data Standout: 76% 12-month CR rate in NMIBC, 80% in BCG-unresponsive patients, with no Grade 3+ adverse events.
Phase III Initiation: Mid-2026 start for two pathways targeting 80,000 U.S. patients/year with no approved therapies.
Financial Security: $160M financing provides liquidity through 2029, supporting full Phase III execution.
Competitive Edge: 80% 12-month CR rate vs. 19% for valrubicin, with unique 5-minute office administration profile.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Relmada Therapeutics (RLMD) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Relmada Therapeutics (RLMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Relmada Therapeutics (RLMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Relmada Therapeutics (RLMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown